Get started
Exelixis, Inc.Exelixis, Inc.Exelixis, Inc.

Exelixis, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

EXEL chart


Full chart

EXEL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.00 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
19.92
Basic EPS (TTM)
1.81 USD
Net income (FY)
‪521.27 M‬ USD
Revenue (FY)
‪2.17 B‬ USD
Shares float
‪270.46 M‬
Beta (1Y)
0.30

Employees


Employees (FY)
‪1.15 K‬
Change (1Y)
−163 −12.44%
Revenue / Employee (1Y)
‪1.89 M‬ USD
Net income / Employee (1Y)
‪454.46 K‬ USD

About Exelixis, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael M. Morrissey
Website
exelixis.com
Headquarters
Alameda
Founded
1994
FIGI
BBG000BQ4WF8
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EXEL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where EXEL is featured.

See all sparks 


Check out other big names from the same industry as EXEL.

Frequently Asked Questions


The current price of EXEL is 36.08 USD — it has increased by 1.22% in the past 24 hours. Watch Exelixis, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Exelixis, Inc. stocks are traded under the ticker EXEL.
EXEL stock has risen by 7.13% compared to the previous week, the month change is a −2.83% fall, over the last year Exelixis, Inc. has showed a 57.35% increase.
We've gathered analysts' opinions on Exelixis, Inc. future price: according to them, EXEL price has a max estimate of 45.00 USD and a min estimate of 29.00 USD. Watch EXEL chart and read a more detailed Exelixis, Inc. stock forecast: see what analysts think of Exelixis, Inc. and suggest that you do with its stocks.
EXEL reached its all-time high on Jul 13, 2000 with the price of 50.50 USD, and its all-time low was 1.26 USD and was reached on Dec 23, 2014. View more price dynamics on EXEL chart.
See other stocks reaching their highest and lowest prices.
EXEL stock is 1.60% volatile and has beta coefficient of 0.30. Track Exelixis, Inc. stock price on the chart and check out the list of the most volatile stocks — is Exelixis, Inc. there?
Today Exelixis, Inc. has the market capitalization of ‪10.00 B‬, it has decreased by −4.26% over the last week.
Yes, you can track Exelixis, Inc. financials in yearly and quarterly reports right on TradingView.
Exelixis, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
EXEL earnings for the last quarter are 0.48 USD per share, whereas the estimation was 0.43 USD resulting in a 12.81% surprise. The estimated earnings for the next quarter are 0.36 USD per share. See more details about Exelixis, Inc. earnings.
Exelixis, Inc. revenue for the last quarter amounts to ‪566.75 M‬ USD, despite the estimated figure of ‪564.43 M‬ USD. In the next quarter, revenue is expected to reach ‪497.19 M‬ USD.
EXEL net income for the last quarter is ‪139.86 M‬ USD, while the quarter before that showed ‪117.97 M‬ USD of net income which accounts for 18.55% change. Track more Exelixis, Inc. financial stats to get the full picture.
No, EXEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has ‪1.15 K‬ employees. See our rating of the largest employees — is Exelixis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exelixis, Inc. EBITDA is ‪718.75 M‬ USD, and current EBITDA margin is 33.14%. See more stats in Exelixis, Inc. financial statements.
Like other stocks, EXEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exelixis, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Exelixis, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Exelixis, Inc. stock shows the buy signal. See more of Exelixis, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.